Asset profile
Belantamab mafodotin
Antibody–drug conjugate
Evidence outlook
Approved: Multiple Myeloma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
92 competitors in this universe: 32 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Belantamab Mafodotin: this drug | Approved | Antibody–drug conjugate | BCMA | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Anitocabtagene Autoleucel | Phase 3 | Cell therapy | BCMA | ||
| Equecabtagene Autoleucel | Phase 3 | Cell therapy | BCMA | ||
| HRC0202 | Phase 2 | Cell therapy | BCMA | ||
| PHE885 | Phase 2 | Cell therapy | BCMA | ||
| AZD4045 | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA CAR-NK (Hrain) | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA CAR-NK (Shenzhen Pregene Biopharma) | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA-CART (Bioray Laboratories) | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech) | Phase 1/2 | Cell therapy | BCMA | ||
| GSK2857914 | Phase 1/2 | Monoclonal antibody | BCMA | ||
| Pamlectabart Tismanitin | Phase 1/2 | Adc (anti-bcma Antibody-targeted Amanitin Conjugate) | BCMA | ||
| SENL103 | Phase 1/2 | Cell therapy | BCMA | ||
| Trovocabtagene Autoleucel (C-CAR088) | Phase 1/2 | Cell therapy | BCMA |
…and 77 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
26 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(30 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
October 2026 (2)
November 2026 (1)
What to watch
2027 (10)
February 2027 (1)
March 2027 (1)
What to watch
April 2027 (2)
July 2027 (1)
What to watch
August 2027 (1)
What to watch
September 2027 (1)
What to watch
October 2027 (2)
December 2027 (1)
What to watch
2028 (5)
January 2028 (1)
What to watch
July 2028 (1)
What to watch
August 2028 (1)
What to watch
September 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (3)
February 2029 (1)
What to watch
April 2029 (1)
What to watch
June 2029 (1)
What to watch
2030 (3)
February 2030 (1)
What to watch
March 2030 (1)
What to watch
August 2030 (1)
What to watch
2031 (3)
April 2031 (1)
What to watch
August 2031 (1)
What to watch
November 2031 (1)
What to watch
2033 (3)
January 2033 (2)
March 2033 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.